Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mallinckrodt plc
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
After missing user fee date due to inspection delay, US FDA clears the CAR-T therapy for treatment of adults with relapsed or refractory large B-cell lymphoma.
Consulting firm agrees to turn over tens of thousands of documents detailing its advice to Purdue, J&J, Endo and Mallinckrodt and pay $537m as part of a deal with 47 states.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aspect Medical Systems, Inc.
- BÂRRX Medical, Inc.
- Cadence Pharmaceuticals, Inc.
- CNS Therapeutics, Inc.
- ev3 Inc.
- Given Imaging Ltd.
- Ikaria Holdings, Inc.
- InfaCare Pharmaceutical Corporation
- INO Therapeutics, LLC
- Mallinckrodt Inc.
- Mallinckrodt Pharmaceuticals
- Micro Therapeutics, Inc.
- Nellcor Puritan Bennett, Inc.
- Ocera Therapeutics Inc. (OCRX)
- Oridion Systems Ltd.
- Questcor Pharmaceuticals, Inc.
- Somanetics Corp.
- Sonorant Inc.
- SpecGx Inc.
- Sucampo Pharmaceuticals, Inc.(SCMP)
- VNUS Medical Technologies
- Stratatech Corporation
- Tranzyme Pharma